Gastric Cancer - Pipeline Review, H1 2016

Description: Gastric Cancer - Pipeline Review, H1 2016

Summary

‘Gastric Cancer - Pipeline Review, H1 2016’, provides an overview of the Gastric Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastric Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastric Cancer
- The report reviews pipeline therapeutics for Gastric Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Gastric Cancer therapeutics and enlists all their major and minor projects
- The report assesses Gastric Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Gastric Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gastric Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus
of indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
Introduction
Gastric Cancer Overview
Therapeutics Development
Gastric Cancer - Therapeutics under Development by Companies
Gastric Cancer - Therapeutics under Investigation by Universities/Institutes
Gastric Cancer - Pipeline Products Glance
Gastric Cancer - Products under Development by Companies
Gastric Cancer - Products under Investigation by Universities/Institutes
Gastric Cancer - Companies Involved in Therapeutics Development
Gastric Cancer - Therapeutics Assessment
Drug Profiles
Gastric Cancer - Recent Pipeline Updates
Gastric Cancer - Dormant Projects
Gastric Cancer - Discontinued Products
Gastric Cancer - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Gastric Cancer, H1 2016
Number of Products under Development for Gastric Cancer - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Development by Companies, H1 2016 (Contd..2)
Number of Products under Development by Companies, H1 2016 (Contd..3)
Number of Products under Development by Companies, H1 2016 (Contd..4)
Number of Products under Development by Companies, H1 2016 (Contd..5)
Number of Products under Development by Companies, H1 2016 (Contd..6)
Number of Products under Development by Companies, H1 2016 (Contd..7)
Number of Products under Development by Companies, H1 2016 (Contd..8)
Number of Products under Development by Companies, H1 2016 (Contd..9)
Number of Products under Development by Companies, H1 2016 (Contd..10)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Products under Development by Companies, H1 2016 (Contd..5)
Products under Development by Companies, H1 2016 (Contd..6)
Products under Development by Companies, H1 2016 (Contd..7)
Products under Development by Companies, H1 2016 (Contd..8)
Products under Development by Companies, H1 2016 (Contd..9)
Products under Development by Companies, H1 2016 (Contd..10)
Products under Development by Companies, H1 2016 (Contd..11)
Products under Development by Companies, H1 2016 (Contd..12)
Products under Development by Companies, H1 2016 (Contd..13)
Products under Development by Companies, H1 2016 (Contd..14)
Products under Development by Companies, H1 2016 (Contd..15)
Products under Investigation by Universities/Institutes, H1 2016
Gastric Cancer - Pipeline by AB Science SA, H1 2016
Gastric Cancer - Pipeline by AbbVie Inc., H1 2016
Gastric Cancer - Pipeline by AbGenomics International, Inc., H1 2016
Gastric Cancer - Pipeline by ADC Therapeutics Sarl, H1 2016
Gastric Cancer - Pipeline by Advaxis, Inc., H1 2016
Gastric Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
Gastric Cancer - Pipeline by Agenus, Inc., H1 2016
Gastric Cancer - Pipeline by Ambrx, Inc., H1 2016
Gastric Cancer - Pipeline by Amgen Inc., H1 2016
Gastric Cancer - Pipeline by arGEN-X BV, H1 2016
Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016
Gastric Cancer - Pipeline by Astellas Pharma Inc., H1 2016
Gastric Cancer - Pipeline by AstraZeneca Plc, H1 2016
Gastric Cancer - Pipeline by Atara Biotherapeutics, Inc., H1 2016
Gastric Cancer - Pipeline by Athenex, Inc., H1 2016
Gastric Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016
Gastric Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2016
Gastric Cancer - Pipeline by Bayer AG, H1 2016
Gastric Cancer - Pipeline by BeiGene, Ltd., H1 2016
Gastric Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016
Gastric Cancer - Pipeline by Bionovis SA, H1 2016
Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Gastric Cancer - Pipeline by Boston Biomedical, Inc., H1 2016
Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
Gastric Cancer - Pipeline by Celgene Corporation, H1 2016
Gastric Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016
Gastric Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016
Gastric Cancer - Pipeline by Celltrion, Inc., H1 2016
Gastric Cancer - Pipeline by Celon Pharma Sp. z o.o., H1 2016
Gastric Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016
Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016
Gastric Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016
Gastric Cancer - Pipeline by Compliment Corporation, H1 2016
Gastric Cancer - Pipeline by Curaxys, S.L., H1 2016
Gastric Cancer - Pipeline by DAE HWA Pharmaceutical Co., Ltd., H1 2016
Gastric Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
Gastric Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016
Gastric Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
Gastric Cancer - Pipeline by Eddingpharm, H1 2016
Gastric Cancer - Pipeline by EirGenix Inc., H1 2016
Gastric Cancer - Pipeline by Eli Lilly and Company, H1 2016
Gastric Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016
Gastric Cancer - Pipeline by Exelixis, Inc., H1 2016
Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Gastric Cancer - Pipeline by Five Prime Therapeutics, Inc., H1 2016
Gastric Cancer - Pipeline by Frost Biologic, Inc., H1 2016
Gastric Cancer - Pipeline by Galena Biopharma, Inc., H1 2016
Gastric Cancer - Pipeline by Genelux Corporation, H1 2016
Gastric Cancer - Pipeline by Genentech, Inc., H1 2016
Gastric Cancer - Pipeline by Gilead Sciences, Inc., H1 2016
Gastric Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
Gastric Cancer - Pipeline by GlycoNex Inc., H1 2016
Gastric Cancer - Pipeline by Glycotope GmbH, H1 2016
Gastric Cancer - Pipeline by Green Cross Corporation, H1 2016
Gastric Cancer - Pipeline by Halozyme Therapeutics, Inc., H1 2016
Gastric Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
Gastric Cancer - Pipeline by Hetero Drugs Limited, H1 2016
Gastric Cancer - Pipeline by Horizon Pharma Plc, H1 2016
Gastric Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016
Gastric Cancer - Pipeline by Ignyta, Inc., H1 2016
Gastric Cancer - Pipeline by Immunomedics, Inc., H1 2016
Gastric Cancer - Pipeline by Incyte Corporation, H1 2016
Gastric Cancer - Pipeline by Innovent Biologics, Inc., H1 2016
Gastric Cancer - Pipeline by INSYS Therapeutics, Inc., H1 2016
Gastric Cancer - Pipeline by ISU ABXIS Co., Ltd., H1 2016
Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016
Gastric Cancer - Pipeline by Johnson & Johnson, H1 2016
Gastric Cancer - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016
Gastric Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
Gastric Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2016
Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
Gastric Cancer - Pipeline by LegoChem Biosciences, Inc, H1 2016
Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2016
Gastric Cancer - Pipeline by MacroGenics, Inc., H1 2016
Gastric Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2016
Gastric Cancer - Pipeline by MedImmune, LLC, H1 2016
Gastric Cancer - Pipeline by Medivation, Inc., H1 2016
Gastric Cancer - Pipeline by Merck & Co., Inc., H1 2016
Gastric Cancer - Pipeline by Merck KGaA, H1 2016
Gastric Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
Gastric Cancer - Pipeline by Mersana Therapeutics, Inc., H1 2016
Gastric Cancer - Pipeline by Merus B.V., H1 2016
Gastric Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
Gastric Cancer - Pipeline by Molecular Targeting Technologies, Inc., H1 2016
Gastric Cancer - Pipeline by MolMed S.p.A., H1 2016
Gastric Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2016
Gastric Cancer - Pipeline by Novartis AG, H1 2016
Gastric Cancer - Pipeline by OBI Pharma, Inc., H1 2016
Gastric Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016
Gastric Cancer - Pipeline by Oncobiologics, Inc., H1 2016
Gastric Cancer - Pipeline by Oncolytics BioPharma Inc., H1 2016
Gastric Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016
Gastric Cancer - Pipeline by OncoTherapy Science, Inc., H1 2016
Gastric Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Gastric Cancer - Pipeline by Panacea Biotec Limited, H1 2016
Gastric Cancer - Pipeline by Patrys Limited, H1 2016
Gastric Cancer - Pipeline by Pfizer Inc., H1 2016
Gastric Cancer - Pipeline by Pharma Mar, S.A., H1 2016
Gastric Cancer - Pipeline by Pharmacyclics, Inc., H1 2016
Gastric Cancer - Pipeline by Puma Biotechnology, Inc., H1 2016
Gastric Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016
Gastric Cancer - Pipeline by Richter Gedeon Nyrt., H1 2016
Gastric Cancer - Pipeline by Sanofi, H1 2016
Gastric Cancer - Pipeline by Sareum Holdings Plc, H1 2016
Gastric Cancer - Pipeline by Sequella, Inc., H1 2016
Gastric Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016
Gastric Cancer - Pipeline by Shionogi & Co., Ltd., H1 2016
Gastric Cancer - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016
Gastric Cancer - Pipeline by Simcere Pharmaceutical Group, H1 2016
Gastric Cancer - Pipeline by Sorrento Therapeutics, Inc., H1 2016
Gastric Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
Gastric Cancer - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016
Gastric Cancer - Pipeline by Supratek Pharma Inc., H1 2016
Gastric Cancer - Pipeline by Synovo GmbH, H1 2016
Gastric Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016
Gastric Cancer - Pipeline by Synthon Holdings BV, H1 2016
Gastric Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
Gastric Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
Gastric Cancer - Pipeline by Takis S.r.l., H1 2016
Gastric Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016
Gastric Cancer - Pipeline by TG Therapeutics, Inc., H1 2016
Gastric Cancer - Pipeline by Transgene SA, H1 2016
Gastric Cancer - Pipeline by Vaxon Biotech, H1 2016
Gastric Cancer - Pipeline by ViiV Healthcare Limited, H1 2016
Gastric Cancer - Pipeline by Zymeworks Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Gastric Cancer Therapeutics - Recent Pipeline Updates, H1 2016
Gastric Cancer - Dormant Projects, H1 2016
Gastric Cancer - Dormant Projects (Contd..1), H1 2016
Gastric Cancer - Dormant Projects (Contd..2), H1 2016
Gastric Cancer - Dormant Projects (Contd..3), H1 2016
Gastric Cancer - Dormant Projects (Contd..4), H1 2016
Gastric Cancer - Dormant Projects (Contd..5), H1 2016
Gastric Cancer - Dormant Projects (Contd..6), H1 2016
Gastric Cancer - Dormant Projects (Contd..7), H1 2016
Gastric Cancer - Dormant Projects (Contd..8), H1 2016
Gastric Cancer - Dormant Projects (Contd..9), H1 2016
Gastric Cancer - Dormant Projects (Contd..10), H1 2016
Gastric Cancer - Discontinued Products, H1 2016
Gastric Cancer - Discontinued Products (Contd..1), H1 2016
Gastric Cancer - Discontinued Products (Contd..2), H1 2016

List of Figures

Number of Products under Development for Gastric Cancer, H1 2016
Number of Products under Development for Gastric Cancer - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016
Ordering:

Order Online - http://www.researchandmarkets.com/reports/3734788/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit 
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Gastric Cancer - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3734788/
Office Code: SCD23GUA

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>☐</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>☐</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>☐</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World